Search

Displaying results 2931 - 2940 of 8010 in total
  1. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

  2. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    [A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

  3. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

    Categories: Antihypertensive Agents Indicated for Hypertension
  4. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics. … In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

  5. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting. … Pharyngitis is normally caused by viruses and proves benign and self-limiting.

  6. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Previously, this drug was indicated only for patients with 17p gene deletion [F2130]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one

  7. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]

    Categories: Antihypertensive Agents Indicated for Hypertension
  8. Drug

    Nedocromil

    go.drugbank.com/drugs/DB00716
    Approved

    A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.

    Categories: Drugs for Obstructive Airway Diseases
  9. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes. … In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.